Veru Inc. (NASDAQ:VERU – Get Rating) – Stock analysts at HC Wainwright reduced their Q3 2023 earnings estimates for Veru in a research note issued on Monday, May 15th. HC Wainwright analyst Y. Chen now expects that the company will post earnings per share of ($0.29) for the quarter, down from their previous estimate of ($0.15). The consensus estimate for Veru’s current full-year earnings is ($1.24) per share. HC Wainwright also issued estimates for Veru’s Q4 2023 earnings at ($0.23) EPS, FY2023 earnings at ($1.39) EPS, Q1 2024 earnings at ($0.21) EPS, Q2 2024 earnings at ($0.17) EPS, Q3 2024 earnings at ($0.12) EPS, Q4 2024 earnings at ($0.11) EPS and FY2024 earnings at ($0.58) EPS.
Separately, Oppenheimer cut their target price on shares of Veru from $14.00 to $9.00 and set an “outperform” rating on the stock in a report on Wednesday, March 15th.
Veru Stock Performance
Institutional Trading of Veru
A number of institutional investors and hedge funds have recently added to or reduced their stakes in VERU. Wipfli Financial Advisors LLC purchased a new stake in Veru in the third quarter worth $25,000. Y Intercept Hong Kong Ltd purchased a new stake in Veru in the first quarter worth $39,000. Deutsche Bank AG lifted its stake in Veru by 41.5% in the first quarter. Deutsche Bank AG now owns 43,396 shares of the company’s stock worth $50,000 after acquiring an additional 12,729 shares during the period. Brinker Capital Investments LLC purchased a new stake in Veru in the fourth quarter worth $59,000. Finally, Price T Rowe Associates Inc. MD lifted its position in Veru by 28.9% during the first quarter. Price T Rowe Associates Inc. MD now owns 52,671 shares of the company’s stock valued at $62,000 after buying an additional 11,810 shares during the period. Hedge funds and other institutional investors own 48.87% of the company’s stock.
Veru Company Profile
Veru, Inc is an oncology biopharmaceutical company, which engages in developing novel medicines for the management of prostate cancer and breast cancer. Its prostate cancer drug candidates include: VERU-111, an oral alpha and beta tubulin inhibitor, which is in a Phase 2 clinical trial for the treatment of metastatic castration and androgen receptor targeting agent resistant prostate cancer, VERU-100, a novel, proprietary, GnRH antagonist peptide drug formulation designed to address the current limitations of commercially available androgen deprivation therapies (ADT) for advanced prostate cancer, and Zuclomiphene Citrate, an oral nonsteroidal estrogen receptor agonist being developed to treat hot flashes, a common side effect caused by ADT.
- Get a free copy of the StockNews.com research report on Veru (VERU)
- It’s Time To Take Another Bite Of Take-Two Interactive
- Zoetis Declares New Dividend, Hinting At Undervaluation
- Good News For Walmart Isn’t So Great For Everybody Else
- Eagle Materials, Answering America’s Building Supply Needs
- Pharma Giants Novartis, Lilly, Merck, and Novo Outperform Market
Receive News & Ratings for Veru Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Veru and related companies with MarketBeat.com's FREE daily email newsletter.